A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Macular Edema After Retinal Vein Occlusion (MK-8748-006)

November 16, 2026 updated by: Merck Sharp & Dohme LLC

Randomized, Double-Masked, Multicenter, 3 Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Macular Edema Following Retinal Vein Occlusion (ME-RVO)

Researchers are looking for new ways to treat macular edema after retinal vein occlusion (ME-RVO). ME-RVO happens when a vein becomes blocked in the retina, the back part of the eye. This blockage causes fluid to leak into the macula, which is the part of the retina that helps to see fine details. The buildup of fluid, called macular edema, can cause blurry vision.

In this trial, researchers want to learn if a trial medicine called MK-8748 can treat ME-RVO. A standard (usual) treatment for ME-RVO is aflibercept. However, standard treatments such as aflibercept may not work for every person.

The main goal of this trial is to learn if participants who receive MK-8748 can see as clearly as participants who receive aflibercept.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

1188

Phase

  • Phase 2
  • Phase 3

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

The main inclusion criteria include but are not limited to the following:

  • Has a diagnosis of macular edema following retinal vein occlusion (ME-RVO) within 4 months (120 days) before screening and is treatment-naïve for ME-RVO
  • Has a BCVA ETDRS letter score between 73 and 19 (20/40 - 20/400 Snellen equivalent), inclusive, in the study eye at screening. In the event that both eyes are eligible, the worst-seeing eye should be enrolled in the trial.
  • Has a decrease in vision in the study eye determined by the investigator to be primarily the result of ME-RVO.

The main exclusion criteria include but are not limited to the following:

  • Has history of stroke (cerebral vascular accident) or myocardial infarction within 180 days prior to study entry
  • Has any active malignancy, except non-melanoma skin carcinoma.
  • Has history of previous episodes of ME-RVO or persistent ME-RVO diagnosed more than 4 months before screening
  • Has any prior steroid implant use including dexamethasone intravitreal implant (Ozurdex®) and fluocinolone acetonide intravitreal implant (Iluvien®) or other intraocular or periocular corticosteroids in the study eye at any time.
  • Has prior periocular pharmacological or intravitreal treatment (including anti-vascular endothelial growth factor medication) for other retinal diseases in the study eye at any time.
  • Has a history of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of screening.
  • Has significant active retinal disease (ie, moderate non-proliferative diabetic retinopathy or worse, proliferative diabetic retinopathy, geographic atrophy, myopic choroidal neovascularization) other than the ME-RVO under investigation in the study eye.
  • Is currently using drugs with known retinal toxicity (eg, hydroxychloroquine, pentosan polysulfate sodium).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: MK-8748 low dose

Participants receive MK-8748 low dose every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96.

Administered via intravitreal (IVT) injection

Other Names:
  • EYE201
Experimental: MK-8748 High Dose

Participants receive MK-8748 high dose every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96.

Administered via intravitreal (IVT) injection

Other Names:
  • EYE201
Active Comparator: Aflibercept 2 mg

Participants receive aflibercept 2 mg every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96.

Administered via IVT injection

Other Names:
  • EYLEA

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean Change in Best-Corrected Visual Acuity (BCVA) (Early Treatment of Diabetic Retinopathy Study [ETDRS] Letters) From Baseline to Week 24
Time Frame: Baseline and Week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 24 will be assessed.

Baseline and Week 24

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean Change in Central Subfield Thickness (CST) from Baseline to Week 24
Time Frame: Baseline and Week 24

Central subfield thickness (CST) in the study eye will be measured in microns using optical coherence tomography (OCT). The mean change in CST from baseline to week 24 will be presented.

Baseline and Week 24
Mean Change in CST from Baseline Over Time
Time Frame: Up to approximately 96 weeks

Central subfield thickness (CST) in the study eye will be measured in microns using optical coherence tomography (OCT). The mean change in CST from baseline over time will be presented.

Up to approximately 96 weeks
Time to Absence of Diabetic Macular Edema (DME)
Time Frame: Up to approximately 96 weeks

The absence of Diabetic Macular Edema (DME) is defined as a Central Subfield Thickness (CST) of <300 μm measured using optical coherence tomography (OCT). The time to absence of Diabetic Macular Edema (DME) in the study eye will be presented.

Up to approximately 96 weeks
Proportion of Participants with Absence of Intraretinal Fluid Over Time
Time Frame: Up to approximately 96 weeks

Participants' intraretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of intraretinal fluid over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with Absence of Subretinal Fluid Over Time
Time Frame: Up to approximately 96 weeks

Participants' subretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of subretinal fluid over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with Absence of Intraretinal Fluid and Subretinal Fluid Over Time
Time Frame: Up to approximately 96 weeks

Participants' subretinal fluid and intraretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of intraretinal and subretinal fluid over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with Resolution of Macular Leakage on Fluorescein Angiography (FA) at Week 24
Time Frame: Week 24

Fluorescein Angiography (FA) images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm^2. The proportion of participants with resolution of macular leakage at Week 24 will be presented.

Week 24
Proportion of Participants with Resolution of Macular Leakage on FA at Week 48
Time Frame: Week 48

FA images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm^2. The proportion of participants with resolution of macular leakage at Week 48 will be presented.

Week 48
Proportion of Participants with Resolution of Macular Leakage on FA at Week 96
Time Frame: Week 96

FA images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm^2. The proportion of participants with resolution of macular leakage at Week 96 will be presented.

Week 96
Mean Change in Vascular Leakage Area on FA in the Macula From Baseline Over Time
Time Frame: Up to approximately 96 weeks

Vascular leakage area in the macula will be evaluated using FA images graded by a centralized reading center. The total area of macular vascular leakage will be measured in square millimeters (mm²). The mean change in vascular leakage area from baseline over time will be presented.

Up to approximately 96 weeks
Mean Change From Baseline in Macular Ischemic Nonperfusion Area as Assessed by Optical Coherence Tomography Angiography (OCT-A)
Time Frame: Up to approximately 96 weeks

Macular ischemic nonperfusion area (defined as areas of capillary nonperfusion or capillary drop-out within the superficial and/or deep retinal capillary plexuses) is measured in square millimeters (mm²) using OCT-A. Images are analyzed and graded by a centralized, masked independent reading center. The mean change in ischemic nonperfusion area from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants Requiring Panretinal Photocoagulation
Time Frame: Up to approximately 96 weeks

The proportion of participants requiring panretinal photocoagulation treatment will be presented.

Up to approximately 96 weeks
Mean Number of Intravitreal (IVT) Injections from Week 48 to Week 96
Time Frame: Up to approximately 48 weeks

The mean number of intravitreal (IVT) Injections from week 48 to week 96 will be presented.

Up to approximately 48 weeks
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 4 Weeks (Q4W) at Week 96
Time Frame: Up to approximately 96 weeks

The proportion of participants on a personalized treatment interval (PTI) of Q4W at Week 96 will be presented.

Up to approximately 96 weeks
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 8 Weeks (Q8W) at Week 96
Time Frame: Up to approximately 96 weeks

The proportion of participants on a personalized treatment interval (PTI) of Q8W at Week 96 will be presented.

Up to approximately 96 weeks
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 12 Weeks (Q12W) at Week 96
Time Frame: Up to approximately 96 weeks

The proportion of participants on a personalized treatment interval (PTI) of Q12W at Week 96 will be presented.

Up to approximately 96 weeks
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 16 Weeks (Q8W) at Week 96
Time Frame: Up to approximately 96 weeks

The proportion of participants on a personalized treatment interval (PTI) of Q16W at Week 96 will be presented.

Up to approximately 96 weeks
Mean Change in BCVA (ETDRS letters) from Baseline Over Time
Time Frame: Baseline and 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The mean change in BCVA (ETDRS) letters from baseline over time will be presented.

Baseline and 96 weeks
Proportion of Participants who Gain ≥5 ETDRS Letters from Baseline at Week 24
Time Frame: Baseline and week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥5 ETDRS letters from baseline to year 1 will be presented.

Baseline and week 24
Proportion of Participants who Gain ≥10 ETDRS Letters from Baseline at Week 24
Time Frame: Baseline and week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥10 ETDRS letters from baseline to year 1 will be presented.

Baseline and week 24
Proportion of Participants who Gain ≥15 ETDRS Letters from Baseline at Week 24
Time Frame: Baseline and week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥15 ETDRS letters from baseline to year 1 will be presented.

Baseline and week 24
Proportion of Participants who Gain ≥5 ETDRS Letters from Baseline Over Time
Time Frame: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥5 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants who Gain ≥10 ETDRS Letters from Baseline Over Time
Time Frame: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥10 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants who Gain ≥15 ETDRS Letters from Baseline Over Time
Time Frame: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥15 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants who Lose ≥5 ETDRS Letters from Baseline at Week 24
Time Frame: Baseline and Week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥5 ETDRS letters from baseline to week 24 will be presented.

Baseline and Week 24
Proportion of Participants who Lose ≥10 ETDRS Letters from Baseline at Week 24
Time Frame: Baseline and Week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥10 ETDRS letters from baseline to week 24 will be presented.

Baseline and Week 24
Proportion of Participants who Lose ≥15 ETDRS Letters from Baseline at Week 24
Time Frame: Baseline and Week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥15 ETDRS letters from baseline to week 24 will be presented.

Baseline and Week 24
Proportion of Participants who Lose ≥5 ETDRS Letters from Baseline Over Time
Time Frame: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥5 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants who Lose ≥10 ETDRS Letters from Baseline Over Time
Time Frame: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥10 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants who Lose ≥15 ETDRS Letters from Baseline Over Time
Time Frame: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥15 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with BCVA Snellen Equivalent of 20/20 or Better at Week 24
Time Frame: Week 24

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/20 or better is defined as ≥84 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/20 or better at week 24 will be presented.

Week 24
Proportion of Participants with BCVA Snellen Equivalent of 20/20 or Better Over Time
Time Frame: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/20 or better is defined as ≥84 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/20 or better over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with BCVA Snellen Equivalent of 20/40 or Better at Week 24
Time Frame: Week 24

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/40 or better is defined as ≥70 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/40 or better at week 24 will be presented.

Week 24
Proportion of Participants with BCVA Snellen Equivalent of 20/40 or Better Over Time
Time Frame: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/40 or better is defined as ≥70 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/40 or better over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with BCVA Snellen Equivalent of 20/200 or Worse at Week 24
Time Frame: Week 24

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/200 or worse is defined as ≤38 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/200 or worse at week 24 will be presented.

Week 24
Proportion of Participants with BCVA Snellen Equivalent of 20/200 or Worse Over Time
Time Frame: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/200 or worse is defined as ≤38 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/200 or worse over time will be presented.

Up to approximately 96 weeks
Change in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Version Composite Score Over Time
Time Frame: Up to approximately 96 weeks

The NEI-VFQ-25 is a validated and reliable 25-item survey that measures the influence of visual disability and visual symptoms on generic health domains (emotional well-being, social functioning and task-oriented domains). The composite score ranges from 0-100 with the higher score indicating better visual function. The change in NEI-VFQ-25 version composite score over time will be presented.

Up to approximately 96 weeks
Number of Participants who Experience a Systemic Adverse Event (AE)
Time Frame: Up to approximately 96 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience a systemic AE will be presented.

Up to approximately 96 weeks
Number of Participants who Experience an Ocular Adverse Event (AE)
Time Frame: Up to approximately 96 weeks

An ocular adverse event (OAE) is defined as any untoward medical occurrence involving the eye or ocular adnexa (including eyelids, conjunctiva, lacrimal apparatus, extraocular muscles, and orbit) that:

Occurs or worsens after the first administration of the investigational product (IP) or a study-related ocular procedure, and does not necessarily have a causal relationship with the IP or procedure.

OAEs include, but are not limited to, changes in: Symptoms (e.g., ocular pain, photophobia, floaters, blurred vision), Visual function (e.g., best-corrected visual acuity [BCVA], visual field). Intraocular pressure (IOP), Anterior segment findings (e.g., conjunctival hyperemia, keratitis, anterior chamber inflammation), Posterior segment findings (e.g., vitreous inflammation, retinal hemorrhages, retinal tears or detachment, macular edema), or ocular adnexa (e.g., eyelid edema, ptosis). The number of participants who experience an ocular AE will be presented.

Up to approximately 96 weeks
Number of Participants who Discontinue Study Treatment Due to an AE
Time Frame: Up to approximately 96 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

Up to approximately 96 weeks
Number of Participants with Antidrug Antibodies (ADA) to MK-8748
Time Frame: At designated time points (up to approximately 96 weeks)

Blood samples collected at designated timepoints will be used to determine the ADA response to MK-8748. The number of participants with ADA to MK-8748 will be presented.

At designated time points (up to approximately 96 weeks)
Maximum Plasma Concentration (Cmax) of MK-8748
Time Frame: At designated time points (up to approximately 96 weeks)

Cmax is defined as the peak concentration over the dosing interval. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax of MK-8748.

At designated time points (up to approximately 96 weeks)
Plasma Trough Concentration (Ctrough) of MK-8748
Time Frame: At designated time points (up to approximately 96 weeks)

Ctrough is defined as the trough concentration. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough of MK-8748.

At designated time points (up to approximately 96 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Medical Director, Merck Sharp & Dohme LLC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 21, 2026

Primary Completion (Estimated)

November 19, 2029

Study Completion (Estimated)

November 19, 2029

Study Registration Dates

First Submitted

November 16, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 8748-006
  • U1111-1342-5647 (Registry Identifier: UTN)
  • 2026-527378-35-00 (Registry Identifier: EU CT)
  • MK-8748-006 (Other Identifier: MSD)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.